We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
- Authors
Athanassiou, Helen; Synodinou, Maria; Maragoudakis, Evagelos; Paraskevaidis, Mihalis; Verigos, Cosmas; Misailidou, Despina; Antonadou, Dosia; Saris, George; Beroukas, Konstantinos; Karageorgis, Pantelis
- Abstract
Surgery remains the standard treatment for glioma, followed by radiotherapy (RT) with or without chemotherapy. Despite multidisciplinary approaches, the median survival time for patients with glioblastoma multiform (GBM) remains at less than 1 year from initial diagnosis. Temozolomide (TMZ), an oral alkylating agent, has shown promising activity in the treatment of malignant gliomas. We conducted a multicenter randomized phase II study comparing the efficacy and safety of TMZ administered concomitantly and sequentially to RT versus RT alone in patients with newly diagnosed GBM.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Vol 23, Issue 10, p2372
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2005.00.331